Need help understanding this study?
Leave your email and we’ll get in touch to discuss your questions and possible next steps.
TerminatedNCT05211947
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
Researchers are studying Iclepertin, tracking side effects to assess long-term safety in people with schizophrenia.
Medication studyAges 18–51Multiple countries
Understand this study
What is this study about?
Researchers are studying Iclepertin, tracking side effects to assess long-term safety in people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 51 years. Other eligibility criteria apply.
- Listed locations
- Anaheim, United States · Bellflower, United States and 253 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 21, 2022
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 1,356
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 51 Years
- Official registry ID
- NCT05211947
- Official title
Show the full official title
An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)
Recruitment & locations
TerminatedAnaheim, United States · Bellflower, United States · Culver City, United States
252 more locations
- Garden Grove, United States
- La Habra, United States
- Long Beach, United States
- Los Angeles, United States
- Orange, United States
- Pico Rivera, United States
- San Diego, United States
- Santa Ana, United States
- Stanford, United States
- Torrance, United States
- Hartford, United States
- New Haven, United States
- Hollywood, United States
- Maitland, United States
- Miami, United States
- Orlando, United States
- Atlanta, United States
- Chicago, United States
- Baltimore, United States
- Gaithersburg, United States
- St Louis, United States
- Omaha, United States
- Marlton, United States
- Cedarhurst, United States
- New York, United States
- Staten Island, United States
- Raleigh, United States
- Cincinnati, United States
- Dayton, United States
- Independence, United States
- Oklahoma City, United States
- Eugene, United States
- State College, United States
- Austin, United States
- Dallas, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- Richmond, United States
- Bellevue, United States
- Banfield, Argentina
- CABA, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Mendoza, Argentina
- Rosario, Argentina
- San Vicente, Argentina
- Melbourne, Australia
- Vienna, Austria
- Bertix, Belgium
- Bierbeek, Belgium
- Duffel, Belgium
- Mechelen, Belgium
- Belo Horizonte, Brazil
- Criciúma, Brazil
- Curitiba, Brazil
- Goiânia, Brazil
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São José do Rio Preto, Brazil
- São Paulo, Brazil
- Plovdiv, Bulgaria
- Calgary, Canada
- Toronto, Canada
- Santiago, Chile
- Segunda Región, Chile
- Baoding, China
- Beijing, China
- Changsha, China
- Guangzhou, China
- Huzhou, China
- Jining, China
- Kunming, China
- Nanjing, China
- Ningbo, China
- Shanghai, China
- Shenzhen, China
- Shijiazhuang, China
- Tianjin, China
- Wuxi, China
- Xi'an, China
- Xinxiang, China
- Zhumadian, China
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Pereira, Colombia
- Rijeka, Croatia
- Zagreb, Croatia
- Klecany, Czechia
- Ostrava, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Říčany, Czechia
- Aalborg, Denmark
- Aarhus N, Denmark
- Glostrup Municipality, Denmark
- Helsinki, Finland
- Turku, Finland
- Bordeaux, France
- Montpellier, France
- Nantes, France
- Nice, France
- Nîmes, France
- Rennes, France
- Rouffach, France
- Saint-Priest-en-Jarez, France
- Bad Homburg, Germany
- Berlin, Germany
- Böblingen, Germany
- Dortmund, Germany
- Mainz, Germany
- Mannheim, Germany
- München, Germany
- Tübingen, Germany
- Westerstede, Germany
- Athens, Greece
- Chaïdári, Greece
- Haidari, Greece
- Heraklion, Greece
- Nea Kifissia, Greece
- Thessaloniki, Greece
- Budapest, Hungary
- Brescia, Italy
- Milan, Italy
- Orbassano (TO), Italy
- Siena, Italy
- Aichi, Konan, Japan
- Aichi, Toyoake, Japan
- Aichi, Toyota, Japan
- Chiba, Chiba, Japan
- Chiba, Ichikawa, Japan
- Fukuoka, Chikugo, Japan
- Fukuoka, Fukuoka, Japan
- Fukuoka, Kurume, Japan
- Fukuoka, Omuta, Japan
- Gumma, Kiryu, Japan
- Hokkaido, Obihiro, Japan
- Hokkaido, Sapporo, Japan
- Hyogo, Kobe, Japan
- Ishikwa, Kahoku-gun, Japan
- Kanagawa, Kawasaki, Japan
- Kanagawa, Yokohama, Japan
- Kochi, Kochi, Japan
- Kumamoto, Kumamoto, Japan
- Kumamoto, Yatsushiro, Japan
- Kyoto, Maizuru, Japan
- Miyagi, Sendai, Japan
- Nagano, Matsumoto, Japan
- Nagano, Suwa, Japan
- Nara, Kashihara, Japan
- Niigata, Niigata, Japan
- Okinawa, Ginowan, Japan
- Osaka, Osaka, Japan
- Saga, Kanzaki-gun, Japan
- Saga, Karatsu, Japan
- Saga, Tosu, Japan
- Saitama, Kumagaya, Japan
- Saitama, Saitama, Japan
- Tochigi, Shimotsuga-gun, Japan
- Tokushima, Tokushima, Japan
- Tokyo, Adachi-ku, Japan
- Tokyo, Bunkyo-ku, Japan
- Tokyo, Kita-ku, Japan
- Tokyo, Kodaira, Japan
- Tokyo, Machida, Japan
- Tokyo, Minato-ku, Japan
- Tokyo, Ota-ku, Japan
- Tokyo, Shibuya-ku, Japan
- Tokyo, Shinjuku-ku, Japan
- Tokyo, Toshima-ku, Japan
- Toyama, Nanto, Japan
- Yamaguchi, Ube, Japan
- Yamanashi, Chuo, Japan
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Ipoh, Perak, Malaysia
- Kuala Lumpur, Malaysia
- Kuching, Malaysia
- Seremban, Malaysia
- Culiacán, Mexico
- Guadalajara, Mexico
- León, Mexico
- Mexico City, Mexico
- Mérida, Mexico
- Monterrey, Mexico
- Nuevo León, Mexico
- San Luis Potosí City, Mexico
- Groningen, Netherlands
- Takpuna Auckland, New Zealand
- Moss, Norway
- Oslo, Norway
- Manila, Philippines, Philippines
- Bełchatów, Poland
- Bialystok, Poland
- Gdansk, Poland
- Gliwice, Poland
- Lodz, Poland
- Poznan, Poland
- Szczecin, Poland
- Warsaw, Poland
- Zabrze, Poland
- Leiria, Portugal
- Bucharest, Romania
- Sibiu, Romania
- Belgrade, Serbia
- Gornja Toponica, Serbia
- Novi Kneževac, Serbia
- Novi Sad, Serbia
- Bojnice, Slovakia
- Košice, Slovakia
- Rimavská Sobota, Slovakia
- Busan, South Korea
- Daegu, South Korea
- Gwangju, South Korea
- Incheon, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Yangsan, South Korea
- Barcelona, Spain
- Collado de Villalba, Spain
- Córdoba, Spain
- Majadahonda, Spain
- Salamanca, Spain
- Seville, Spain
- Valencia, Spain
- Vigo, Spain
- Zamora, Spain
- Helsingborg, Sweden
- Uppsala, Sweden
- Kaohsiung City, Taiwan
- Keelung, Taiwan
- Taichung, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Ankara, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Manisa, Türkiye
- Nove, Ukraine
- Bodmin, United Kingdom
- Cheltenham, United Kingdom
- Chester, United Kingdom
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
- Southampton, United Kingdom
- Czechia
- Türkiye
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are studying Iclepertin, tracking side effects to assess long-term safety in people with schizophrenia.
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Does this study involve medication?
Yes. The study involves medication, including Iclepertin.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 51 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT00159757
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
Hungary
TerminatedNCT01568216
20101299: Study Effect of AMG 747 on Schizophrenia Negative Symptoms
United States, Australia, Canada, + 4 others
TerminatedNCT01568229
20110165: Study Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
United States, France, United Kingdom, + 3 others